Plus Therapeutics, Inc. (PSTV)
PSTV Stock Price Chart
Explore Plus Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze PSTV price movements and trends.
PSTV Company Profile
Discover essential business fundamentals and corporate details for Plus Therapeutics, Inc. (PSTV) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
11 Jul 2001
Employees
21.00
Website
https://www.plustherapeutics.comCEO
Marc H. Hedrick
Description
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
PSTV Financial Timeline
Browse a chronological timeline of Plus Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 28 May 2026
Upcoming earnings on 13 Nov 2025
EPS estimate is -$0.07, while revenue estimate is $1.50M.
Earnings released on 14 Aug 2025
EPS came in at -$0.01 surpassing the estimated -$0.09 by +88.89%, while revenue for the quarter reached $1.39M , missing expectations by -23.91%.
Earnings released on 30 May 2025
EPS came in at -$0.56 falling short of the estimated -$0.17 by -229.41%, while revenue for the quarter reached $1.06M , missing expectations by -6.90%.
Earnings released on 27 Mar 2025
EPS came in at -$0.67 falling short of the estimated -$0.51 by -31.37%, while revenue for the quarter reached $1.40M , beating expectations by +39.47%.
Earnings released on 14 Nov 2024
EPS came in at -$0.46 matching the estimated -$0.46, while revenue for the quarter reached $1.46M , beating expectations by +22.10%.
Earnings released on 14 Aug 2024
EPS came in at -$0.71 falling short of the estimated -$0.53 by -33.96%, while revenue for the quarter reached $1.28M , missing expectations by -23.41%.
Earnings released on 15 May 2024
EPS came in at -$0.75 surpassing the estimated -$1.09 by +31.19%, while revenue for the quarter reached $1.68M , missing expectations by -0.77%.
Earnings released on 5 Mar 2024
EPS came in at -$0.70 surpassing the estimated -$0.78 by +10.26%, while revenue for the quarter reached $1.31M , beating expectations by +23.87%.
Earnings released on 31 Oct 2023
EPS came in at -$1.00 falling short of the estimated -$0.58 by -72.41%, while revenue for the quarter reached $1.24M , missing expectations by -3.88%.
Earnings released on 14 Aug 2023
EPS came in at -$0.59 surpassing the estimated -$1.91 by +69.11%, while revenue for the quarter reached $1.85M , beating expectations by +134.68%.
Stock split effective on 1 May 2023
Shares were split 1 : 15 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 20 Apr 2023
EPS came in at -$2.10 matching the estimated -$2.10, while revenue for the quarter reached $506.00K , missing expectations by -31.62%.
Earnings released on 23 Feb 2023
EPS came in at -$2.40 falling short of the estimated -$2.25 by -6.67%, while revenue for the quarter reached $224.00K , missing expectations by -84.90%.
Earnings released on 20 Oct 2022
EPS came in at -$2.85 surpassing the estimated -$3.15 by +9.52%, while revenue for the quarter reached $100.00K , missing expectations by -66.67%.
Earnings released on 21 Jul 2022
EPS came in at -$3.60 falling short of the estimated -$2.70 by -33.33%.
Earnings released on 21 Apr 2022
EPS came in at -$2.85 falling short of the estimated -$2.55 by -11.76%.
Earnings released on 24 Feb 2022
EPS came in at -$4.05 falling short of the estimated -$3.45 by -17.39%.
Earnings released on 21 Oct 2021
EPS came in at -$4.20 falling short of the estimated -$3.15 by -33.33%.
Earnings released on 22 Jul 2021
EPS came in at -$3.75 falling short of the estimated -$3.45 by -8.70%.
Earnings released on 22 Apr 2021
EPS came in at -$4.95 falling short of the estimated -$4.65 by -6.45%.
Earnings released on 22 Feb 2021
EPS came in at -$10.94 falling short of the estimated -$4.95 by -121.01%.
Earnings released on 22 Oct 2020
EPS came in at -$5.85 falling short of the estimated -$0.55 by -963.64%.
PSTV Stock Performance
Access detailed PSTV performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.